Acute coronary syndromes complicating the first infusion of rituximab

Clinical Lymphoma and Myeloma

Volumn 8, Issue 4, 2008, Pages 253-255

  Armitage, Joel D ^a   Montero, Carlos ^b   Benner, Alisha ^a   Armitage, James O ^a   Bociek, Gregory ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b Complejo Hospitalario Metropolitano ^*  (Panama)

Author keywords

Acute myocardial infarction; Burkitt lymphoma; Coronary artery disease; Lactate dehydrogenase

Indexed keywords

DIPHENHYDRAMINE; LACTATE DEHYDROGENASE; PARACETAMOL; RITUXIMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ASYSTOLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; BURKITT LYMPHOMA; CASE REPORT; CHRONIC LYMPHATIC LEUKEMIA; CORONARY ARTERY DISEASE; ENZYME BLOOD LEVEL; HEART ARRHYTHMIA; HEART MUSCLE ISCHEMIA; HUMAN; LYMPHOCYTOSIS; LYMPHOPROLIFERATIVE DISEASE; MALE; MEDICAL RECORD REVIEW; RISK FACTOR; THORAX PAIN; CHEMICALLY INDUCED DISORDER; MIDDLE AGED; NONHODGKIN LYMPHOMA;

ACUTE CORONARY SYNDROME; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED;

EID: 60849108963     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2008.n.035     Document Type: Article

References (14)

1. Fisher RI, LeBlanc M, Press OW, et al. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol 2005; 23:8447-52.
2. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23:5027-33.
3. Smolen JS, Keystone EC, Emery P, et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 2007; 66:143-50.
4. Rituxan® (Rituximab) [prescribing information]: South San Francisco, CA: Biogen Idec and Genentech BioOncology; April 2001.
5. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90:2188-95.
6. Byrd JC, Murphy T, Howard RS, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001; 19:2153-64.
7. Winkler U, Jensen M, Manzke O, et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999; 94:2217-24.
8. Byrd JC, Waselenko JK, Maneatis TJ, et al. Rituximab therapy in hematologic malignancy patients with circulating blood tumor cells: association with increased infusion-related side effects and rapid blood tumor clearance. J Clin Oncol 1999; 17:791-5.
9. Huhn D, von Schilling C, Wilhelm M, et al. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001; 98:1326-31.
10. O'Brien SM, Kantarjian H, Thomas DA, et al. Rituximab doseescalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001; 19:2165-70.
11. Igarashi T, Kobayashi Y, Ogura M, et al. Factors affecting toxicity, response and progression-free survival in relapsed patients with indolent B-cell lymphoma and mantle cell lymphoma treated with rituximab: a Japanese phase II study. Ann Oncol 2002; 13:928-43.
12. Foran JM, Rohatiner AZ, Cunningham D, et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000; 18:317-24.
13. Hainsworth JD, Burris HA III, Morrissey LH, et al. Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma. Blood 2000; 95:3052-6.
14. Byrd JC, Peterson BL, Morrison VA, et al. Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712). Blood 2003; 101:6-14.